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Vaccine ageism: the exclusion of older people from Indonesia’s national COVID-19 
vaccination programme. 
Dear Editor 
Concern about vaccine nationalism is important and well-founded, but it has overshadowed 
another key form of injustice: vaccine ageism.  
In many low and middle-income countries (LMICs), SINOVAC is the main form of currently 
available COVID19 vaccine. Initial SINOVAC trials in China were only conducted on adults 
aged under 60 [1]. Due to the lack of published evidence, the government of Indonesia has 
decided to exclude people aged 60 and over from its vaccine roll-out [2].  
Further trials of SINOVAC for people at older ages have since begun in countries such as 
Brazil [3]. Yet ongoing SINOVAC trials in Indonesia continue to exclude older people.  
According to clinical trial research team leader, Kusnandi Rusmil, “Why do we target people 
of a productive age? These people can work hard, so the country will not have a deficit" [4]. 
This justification follows an established tradition of using sweeping and inaccurate 
generalisations about older people’s “public value” to justify ageist discrimination [5]. 
Indonesia’s unusual vaccination policy will lead to reservoirs of Covid-19 older people, 
resulting in continuing viral transmission, more hospital admissions and avoidable deaths. 
Not all candidate COVID-19 vaccine trials have excluded older people. Nevertheless, there is 
a long and problematic history of excluding older people from trials of vaccines or 
treatments for conditions that affect them greatly [6]. Media reports suggest that SINOVAC 
may be effective for older people, but at a lower level than for other ages [7]. However, 
related findings are yet to be published. It remains to be seen whether countries like 
Indonesia will respond when new SINOVAC data are published or new vaccines become 
available.   
For now, nationalist self-interest means most LMICs are at the back of the global vaccine 
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